Company makes 50.50% capital contribution in newly incorporated Lifescience LLP as subscribing partner

Emrock Corporation Ltd has made a 50.50% capital contribution to newly incorporated Emrock Lifescience LLP as a subscribing partner.

Mon 5 Oct 2026

Capital Contribution

50.50%

Company's Capital Subscription Obligation

Rs. 50500/-

LLP Total Obligation

Rs. 100,000

Consideration

Cash towards contribution to capital

LLP Incorporation Date

05.10.2026

What the company disclosed

Emrock Corporation Ltd (formerly Vaghani Techno-Build Limited) has made a contribution of 50.50% in the capital of Emrock Lifescience LLP (LLPIN-ADC-8815) as a subscribing partner. The intimation was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The numbers involved

• The LLP's total obligation is Rs. 100,000, and the company's obligation to subscribe to the capital is Rs. 50500/-.
• The consideration is cash towards contribution to capital, and the cost stated is Rs. 50500/- as partner's contribution.
• The company is to invest 50.50% in contribution as a partner of the LLP.

About the LLP

• Emrock Lifescience LLP was incorporated on 05.10.2026 and its registered office is at 715, Accolade-2, S No. 750/2/2, F.P. 131, Sola, Ahmedabad, Gujarat, India, 380060.
• Its stated business covers manufacturing, processing, formulating, importing, exporting, trading, marketing, distributing, wholesaling and retailing of pharmaceutical, medicinal, healthcare, nutraceutical and allied products, including bulk drugs, APIs, drug intermediates, formulations, antibiotics, vitamins, vaccines and veterinary medicines.
• Turnover is shown as not applicable for 2023-24, 2024-25 and 2025-26, the LLP being newly incorporated.

Related party angle

• The LLP is promoted by Emrock Corporation Ltd, which is a subscriber to the LLP, so the transaction falls under related party transactions.
• Directors of the company, Mr. Arjunbhai Jagdishbhai Patel and Mr. Parth Tulsibhai Patel, are also Designated Partners of the LLP.
• The company says the investment is part of its strategic initiative to invest in pharmaceutical projects.

What an investor can take away

The update records a fresh cash contribution by the company into a newly formed LLP that is yet to begin operations, which is why no turnover history is shown for the LLP. The stated purpose is a strategic move into pharmaceutical projects, an area outside the company's earlier name association as a techno-build entity. Because the LLP is promoted by the company and shares two directors with it, the transaction sits in the related party category. No governmental or regulatory approval is stated as required for the incorporation, and the indicative time period for completion of the acquisition is shown as not applicable.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.